Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer

NCT01462890 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

927

Enrollment

OTHER

Sponsor class

Conditions

Genital Diseases, Female
Ovarian Diseases
Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Paclitaxel
DRUG: Carboplatin
OTHER: specialized pathology review (Germany only)

Sponsor

AGO Study Group

Collaborators

[object Object]
[object Object]